Sign In
Buy AUTL
$1.62
-0.130 (-7.43%)
At Close: Jun 03, 2026
Autolus Therapeutics plc (AUTL) Q2 2023 Earnings Call Transcript
07:59am, Sunday, 06'th Aug 2023
Autolus Therapeutics plc (NASDAQ:AUTL ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Dr. Christian Itin - CEO Dr. Lucinda Crabtree - CFO Rob Dolski - incoming CFO Ju
Autolus Therapeutics to report second quarter 2023 financial results and host conference call on August 3, 2023
07:00am, Tuesday, 18'th Jul 2023
LONDON, July 18, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced t
Autolus Therapeutics Could Hold A Winning CAR T-Cell Ticket
07:34pm, Friday, 30'th Jun 2023
Obe-cel and pipeline offer many catalysts in 2023. The CAR T-cell candidate offer a safer alternative to commercial rivals. Strong cash position should see the company through to obe-cel launch.
3 Top Penny Stock Picks You Haven't Heard Of
09:39am, Wednesday, 14'th Jun 2023
Unless you regularly invest in or research penny stocks it's likely you aren't familiar with most companies in the space. These penny stock picks aren't household names because by and large they aren
Autolus Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023
07:00am, Thursday, 20'th Apr 2023
LONDON, April 20, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced
Autolus Therapeutics (AUTL) Q4 2022 Earnings Call Transcript
02:04pm, Tuesday, 07'th Mar 2023
Autolus Therapeutics plc (NASDAQ:AUTL ) Q4 2022 Earnings Conference Call March 7, 2023 8:30 AM ET Company Participants Christian Itin - Chief Executive Officer Lucinda Crabtree - Chief Financial Offic
Autolus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 7, 2023
07:00am, Wednesday, 15'th Feb 2023
LONDON, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced t
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
10:00am, Monday, 12'th Dec 2022
LONDON, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces t
Why Autolus Therapeutics Stock Is Crashing Today
11:31am, Friday, 09'th Dec 2022
The biopharmaceutical company announced the pricing of a secondary stock offering.
Autolus Therapeutics: Near-Term Catalyst Plus Several Bio Deals Could Shift Momentum
06:21am, Wednesday, 16'th Nov 2022
Results from the pivotal FELIX phase 2 clinical study using obe-cel for the treatment of patients with relapsed/refractory Acute Lymphoblastic Leukemia expected in Q4 of 2022. With positive results, a
Autolus Therapeutics plc (AUTL) Q3 2022 Earnings Call Transcript
10:15pm, Friday, 04'th Nov 2022
Autolus Therapeutics plc (NASDAQ:AUTL ) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Olivia Manser - Director, Investor Relations Christian Itin - Chief Executive
Autolus Therapeutics to Present Three Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
09:31am, Thursday, 03'rd Nov 2022
LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces t
Autolus Therapeutics to Report Third Quarter 2022 Financial Results on November 3, 2022
07:00am, Friday, 21'st Oct 2022
LONDON, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced t
Autolus Therapeutics: Overlooked CAR-T Player With Key Catalysts Approaching
08:00am, Wednesday, 17'th Aug 2022
Shares of AUTL have lost a third of their value over the past year. Sentiment in the autologous CAR-T space is improving as lead players successfully grow sales and scale up to meet demand.
Autolus Therapeutics plc (AUTL) CEO Christian Itin on Q2 2022 Results - Earnings Call Transcript
11:59pm, Sunday, 07'th Aug 2022
Autolus Therapeutics plc (NASDAQ:AUTL ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Olivia Manser - Director, IR Christian Itin - CEO Lucinda Crabtree - CFO Confere
